Several somatic copy number variations (CNVs) have been identified in papillary thyroid cancer (PTC). However， the functional roles of CNVs and the genes responsible for the roles of CNVs are largely unknown. In this study， we identified a novel long noncoding RNA (lncRNA) CNALPTC1 (copy number amplified long noncoding RNA in papillary thyroid cancer 1). The genomic copy number of is amplified and CNALPTC1 expression level is up-regulated in PTC. Increased expression of CNALPTC1 is associated with aggressive clinicopathological characteristics. Gain-of-function and loss-of-function assays revealed that CNALPTC1 promotes proliferation and migration of PTC cells， and inhibits apoptosis of PTC cells. Mechanistically， we found that CNALPTC1 physically associates to miR-30 family and down-regulates miR-30 expression. Furthermore， CNALPTC1 up-regulates the expression of miR-30 targets， such as BCL9， SNAI1， and VIM. The mutation of miR-30 binding site on CNALPTC1 or overexpression of miR-30 abrogates the oncogenic roles of CNALPTC1 in PTC. Collectively， our results suggested that the copy number amplified lncRNA CNALPTC1 promotes PTC progression via sponging miR-30 family. Our data also implied that CNALPTC1 may be a novel therapeutic target for PTC.